Lipocine vs Ovid Therapeutics
LPCN and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and OVID compare
Ovid Therapeutics is the larger company, worth 33 times as much as Lipocine ($434M against $13.2M).
Lipocine grew revenue faster over the last twelve months (−62.7% versus −76.2% for Ovid Therapeutics).
Lipocine keeps more of each dollar of sales as profit, with a net margin of −755% compared with −2179% at Ovid Therapeutics.
Ovid Therapeutics scores higher on the StockData Score (10 against 9 for Lipocine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | OVID |
|---|---|---|
| Size and price | ||
| Market cap | $13.2M | $434M |
| Share price | $1.60 | $2.22 |
| Change, 1 year | −44.3% | 70.1% |
| Change, 5 years | −91.7% | −31.9% |
| Beta (5Y) | −0.38 | 1.34 |
| Employees | 14 | 23 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.4× (better) | 274× |
| P/B | 0.6× (better) | 2.1× |
| Fair value | $2.64 | – |
| Margin of safety | 39.3% | – |
| Growth | ||
| Revenue growth (TTM) | −62.7% (better) | −76.2% |
| Revenue growth, 5Y average | – | −10.5% |
| Profitability | ||
| Operating margin | −801% (better) | −3687% |
| Net margin | −755% (better) | −2179% |
| Return on equity | −60.9% | −26.0% (better) |
| Return on invested capital | – | −160% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.48 | 12.39 (better) |
| Altman Z-score | −9.43 | 9.41 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −123% | – |
| Shareholder yield | −123% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 75.3% |
| Held by insiders | 9.0% | 13.6% |
| Insider net buying, 12 months | $596K (better) | −$29.3K |
| Short interest, % of float | 4.3% | 10.8% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.